Bullish Moving Averages
15
Bearish Moving Averages
1
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
804.30Today’s High
821.0052W low
477.6052W High
840.00Open Price
821.00Prev. Close
635.5500Volume
226051.00Value
183915093.60Fundamentals
Market Cap
20711.40
Price to Earnings
69.00
Price to Book Value
10.10
Dividend Yield
0.00
PE to Growth
-2.60
Op Revenue TTM
1051.35
Net Profit TTM
300.28
Cash From Operating Activity
358.48
Return on Equity %
14.64
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
66.3
Week
59.2
Month
40.5
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
812.98
PIVOT
First Resistance
821.67
Second Resistance
829.73
Third Resistance
838.42
First Support
804.92
Second Support
796.23
Third Support
788.17
Relative Strength Index
70.78
Money Flow Index
84.73
MACD
43.7
MACD Signal
35.65
Average True Range
28.13
Average Directional Index
36.77
Rate of Change (21)
29.05
Rate of Change (125)
10.13
Commodity Channel Index
98.5
Williams %R
-18.3
BETA
1 Month
0.67
3 Month
0.05
1 Year
0.31
3 Year
0.17
PRICE CHANGE ANALYSIS
↑ 3.33%
1 Week
Low
High
769.1
839.95
↑ 31.61%
1 Month
Low
High
614.75
839.95
↑ 26.02%
3 Months
Low
High
598
839.95
↑ 8.35%
6 Months
Low
High
585.2
839.95
↑ 67.87%
1 Year
Low
High
477.65
839.95
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 260.39 | 226.79 | 238.82 | 354.08 | 375.14 | 361.00 | 288.79 | 349.70 | 498.24 | 400.86 | 339.32 | |
| Operating Expenses Qtr | 171.38 | 144.69 | 127.27 | 174.14 | 189.76 | 201.42 | 171.76 | 184.06 | 206.28 | 205.56 | 179.21 | |
| Operating Profit Qtr | 72.14 | 68.14 | 97.35 | 169.88 | 174.63 | 147.07 | 106.64 | 154.74 | 157.57 | 186.03 | 121.78 | |
| EBIDT Qtr Cr | 89.01 | 82.10 | 111.55 | 179.94 | 185.38 | 159.58 | 117.03 | 165.64 | 291.96 | 195.30 | 160.11 | |
| Depreciation Qtr | 15.66 | 11.33 | 10.48 | 11.15 | 10.63 | 10.91 | 10.76 | 10.55 | 10.42 | 10.51 | 9.18 | |
| Net Profit Qtr | 53.43 | 52.36 | 74.73 | 124.29 | 130.16 | 109.47 | 78.92 | 114.05 | 224.46 | 137.00 | 115.20 | |
| Basic EPS Qtr | 2.10 | 2.06 | 2.94 | 4.88 | 5.11 | 4.30 | 3.10 | 4.48 | 8.82 | 5.38 | 4.53 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 1080.09 | 1374.63 | 1508.01 | 1023.96 | 851.91 | |
| Operating Expenses Annual Cr | 615.09 | 747.00 | 740.23 | 569.20 | 448.64 | |
| Operating Profit Annual | 409.90 | 583.08 | 579.99 | 440.52 | 385.15 | |
| Operating Profit Margin Annual % | 37.95 | 42.42 | 38.46 | 43.02 | 45.21 | |
| Total Expenses Annual Cr | 671.31 | 795.24 | 785.56 | 609.98 | 494.32 | |
| EBIDT Annual Cr | 464.99 | 627.63 | 767.78 | 454.76 | 403.26 | |
| EBIDT Annual margin % | 43.05 | 45.66 | 50.91 | 44.41 | 47.34 | |
| Depreciation | 48.79 | 42.84 | 39.10 | 31.64 | 23.86 | |
| PAT Before ExtraOrdinary Items Annual Cr | 304.82 | 432.60 | 558.10 | 308.65 | 270.08 | |
| Net Profit Annual | 304.82 | 432.60 | 558.10 | 308.65 | 270.08 | |
| Basic EPS Annual | 11.97 | 16.99 | 21.92 | 12.12 | 21.22 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 2055.90 | 1749.38 | 1520.69 | 1065.18 | 782.83 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 79.38 | 54.77 | 75.19 | 73.91 | 127.68 | |
| Total Current Liabilities Annual Cr | 105.44 | 154.18 | 209.00 | 219.74 | 200.38 | |
| Total Capital Plus Liabilities Annual Cr | 2240.72 | 1958.33 | 1804.89 | 1358.83 | 1110.88 | |
| Fixed Assets Annual | 702.62 | 676.84 | 564.19 | 537.48 | 458.45 | |
| Total Non Current Assets Annual | 1031.16 | 1003.21 | 695.93 | 794.13 | 719.35 | |
| Total Current Assets Annual | 1209.55 | 955.12 | 1108.96 | 564.69 | 391.53 | |
| Total Assets Annual | 2240.72 | 1958.33 | 1804.89 | 1358.83 | 1110.88 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 190.84 | 29.38 | 47.70 | 78.83 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 370.65 | 484.17 | 269.89 | 329.73 | 367.78 | |
| Cash from Investing Activity Annual | -381.58 | -235.57 | -90.36 | -257.66 | -374.73 | |
| Cash from Financing Annual Activity | -13.78 | -235.79 | -156.41 | -76.55 | 7.62 | |
| Net Cash Flow Annual | - | 12.81 | 23.12 | -4.48 | 0.67 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 80.76 | 68.72 | 59.74 | 41.84 | 61.50 | |
| ROE Annual % | 14.82 | 24.72 | 36.70 | 28.97 | 34.50 | |
| ROCE Annual % | 19.49 | 32.41 | 45.65 | 37.14 | 41.66 | |
| Total Debt to Total Equity Annual | 0.02 | 0.04 | 0.06 | 0.13 | 0.24 | |
| EBDIT Annual Margin % | 45.36 | 47.18 | 58.15 | 45.03 | 48.36 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 269.98 | 234.16 | 250.90 | 358.22 | 380.76 | 366.78 | 289.32 | 349.83 | 380.72 | 456.27 | 306.03 | |
| Operating Expenses Qtr | 179.59 | 154.68 | 133.09 | 180.58 | 200.28 | 207.08 | 178.52 | 187.92 | 206.83 | 205.56 | 179.21 | |
| Operating Profit Qtr | 73.34 | 65.14 | 97.96 | 166.97 | 169.08 | 146.69 | 99.88 | 150.88 | 157.02 | 186.02 | 121.78 | |
| EBIDT Qtr Cr | 90.40 | 79.49 | 117.80 | 177.63 | 180.48 | 159.71 | 110.80 | 161.92 | 173.89 | 250.71 | 126.82 | |
| Depreciation Qtr | 17.25 | 12.75 | 11.89 | 12.54 | 11.96 | 12.24 | 12.03 | 11.50 | 10.42 | 10.51 | 9.18 | |
| Net Profit Qtr | 53.37 | 46.75 | 79.56 | 120.59 | 123.97 | 107.72 | 72.06 | 107.54 | 91.67 | 160.07 | 96.98 | |
| Basic EPS Qtr | 2.10 | 1.84 | 3.13 | 4.74 | 4.87 | 4.23 | 2.83 | 4.22 | 3.60 | 6.29 | 3.81 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 1113.26 | 1386.69 | 1412.60 | 1023.96 | 851.91 | |
| Operating Expenses Annual Cr | 645.54 | 773.79 | 740.80 | 569.24 | 448.68 | |
| Operating Profit Annual | 405.81 | 566.53 | 579.43 | 440.48 | 385.11 | |
| Operating Profit Margin Annual % | 36.45 | 40.86 | 41.02 | 43.02 | 45.21 | |
| Total Expenses Annual Cr | 707.59 | 826.96 | 786.12 | 610.02 | 495.61 | |
| EBIDT Annual Cr | 467.72 | 612.90 | 671.81 | 454.72 | 403.23 | |
| EBIDT Annual margin % | 42.01 | 44.20 | 47.56 | 44.41 | 47.33 | |
| Depreciation | 54.60 | 47.73 | 39.10 | 31.64 | 23.86 | |
| PAT Before ExtraOrdinary Items Annual Cr | 300.28 | 411.29 | 412.69 | 308.61 | 268.79 | |
| Net Profit Annual | 300.28 | 411.29 | 453.80 | 362.34 | 317.00 | |
| Basic EPS Annual | 11.80 | 16.16 | 17.83 | 14.23 | 24.91 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 2050.66 | 1735.18 | 1527.18 | 1180.81 | 844.76 | |
| Minority Interest Liability Annual Cr | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non Current Liabilities Annual Cr | 96.53 | 71.79 | 92.11 | 73.91 | 127.68 | |
| Total Current Liabilities Annual Cr | 106.90 | 158.77 | 210.29 | 219.75 | 200.37 | |
| Total Capital Plus Liabilities Annual Cr | 2254.09 | 1965.74 | 1829.59 | 1474.47 | 1172.81 | |
| Fixed Assets Annual | 848.70 | 828.42 | 564.19 | 537.48 | 458.45 | |
| Total Non Current Assets Annual | 990.90 | 954.70 | 701.66 | 909.68 | 781.16 | |
| Total Current Assets Annual | 1263.19 | 1011.05 | 1127.93 | 564.79 | 391.65 | |
| Total Assets Annual | 2254.09 | 1965.74 | 1829.59 | 1474.47 | 1172.81 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 40.43 | 29.38 | 47.70 | 78.83 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 358.48 | 450.91 | 330.00 | 383.44 | 415.95 | |
| Cash from Investing Activity Annual | -362.25 | -194.84 | -136.21 | -311.40 | -421.53 | |
| Cash from Financing Annual Activity | -13.80 | -235.83 | -156.41 | -76.55 | 6.37 | |
| Net Cash Flow Annual | - | 20.24 | 37.38 | -4.51 | 0.79 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 80.56 | 68.16 | 59.99 | 46.39 | 66.37 | |
| ROE Annual % | 14.64 | 23.70 | 29.71 | 30.68 | 37.52 | |
| ROCE Annual % | 19.24 | 31.27 | 39.07 | 33.71 | 39.01 | |
| Total Debt to Total Equity Annual | 0.02 | 0.00 | 0.06 | 0.12 | 0.22 | |
| EBDIT Annual Margin % | 44.48 | 45.72 | 50.88 | 45.03 | 48.36 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY P | 1.11 | 74803290 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| BERHYANDA LIMITED | 50.1 | 74803279 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| DSP EQUITY SAVINGS FUND | 5.91 | 74803282 |
| UTI-UNIT LINKED INSURANCE PLAN | 3.76 | 74803283 |
| HSBC MIDCAP FUND | 1.57 | 74803284 |
| GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY P | 1.11 | 74803290 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (initscapacityassoletrusteeofJastiFamilyTrust) | 9.9 | 74803297 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Sep 09, 2022 | 1 | INTERIM | Sep 12, 2022 | Equity Share |
| Sep 09, 2022 | 5 | SPECIAL | Sep 12, 2022 | Equity Share |
| May 13, 2022 | 1 | INTERIM | May 17, 2022 | Equity Share |
| May 13, 2022 | 1 | SPECIAL | May 17, 2022 | Equity Share |
| Feb 15, 2022 | 1 | INTERIM | Feb 16, 2022 | Equity Share |
| Feb 15, 2022 | 2 | SPECIAL | Feb 16, 2022 | Equity Share |
| Aug 13, 2021 | 1 | FINAL | Aug 17, 2021 | Equity Share |
| Feb 17, 2021 | 1 | INTERIM | Feb 18, 2021 | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 30, 2024 | Audited Results | (Revised) |
| Feb 05, 2024 | Quarterly Results | - |
| Nov 09, 2023 | Quarterly Results | - |
| Aug 08, 2023 | Quarterly Results | - |
| May 25, 2023 | Audited Results | - |
| Feb 06, 2023 | Quarterly Results | - |
| Nov 08, 2022 | Quarterly Results | - |
| Aug 08, 2022 | Quarterly Results | - |
| May 09, 2022 | Audited Results & Interim Dividend | - |
| Feb 08, 2022 | Quarterly Results & Interim Dividend | - |
| Nov 06, 2021 | Quarterly Results | - |
| Aug 13, 2021 | Quarterly Results | - |
| Jun 08, 2021 | Audited Results & Final Dividend | - |
| Feb 10, 2021 | Quarterly Results & Interim Dividend | - |
| Oct 30, 2020 | Quarterly Results | - |
| Aug 17, 2020 | Quarterly Results & ESOP | - |
| Jun 18, 2020 | Audited Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
| Sep 25, 2020 | 1:1 | 2020-09-28 |
28 Jun 2024
Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window
Intimation of closure of Trading Window
21 Jun 2024
Suven Pharmaceuticals Ltd - 543064 - Transcript Of The Conference Call For Acquisition Of A Majority Stake In Sapala Organics
Transcript of the conference call for acquisition of a majority stake in Sapala Organics
21 Jun 2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DB Trustee (Hong Kong) Ltd
19 Jun 2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our conference call intimation dated June 13, 2024, the audio recording of the conference call for acquisition of a majority stake in Sapala Organics held on Wednesday, June 19, 2024, has been uploaded on the Company''s website
19 Jun 2024
Suven Pharmaceuticals Business Update Call
Conference Call with Suven Pharmaceuticals Management and Analysts to discuss the acquisition of Sapala Organics. Listen to the full transcript.
19 Jun 2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June 18, 2024 for Berhyanda Ltd & Berhyanda Midco Ltd
19 Jun 2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CSCGlobal Capital Markets Singapore Pte Ltd
18 Jun 2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 18, 2024 for Berhyanda Ltd & Berhyanda Midco Ltd
18 Jun 2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 18, 2024 for Berhyanda Ltd & Berhyanda Midco Ltd
15 Jun 2024
Suven Pharmaceuticals Ltd - 543064 - Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Update on amalgamation of Casper Pharma Pvt Ltd (WOS) into and with Suven Pharmaceuticals Limited is attached.
